GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Navco Pharmaceuticals Inc (TSXV:NAV) » Definitions » Capex-to-Operating-Cash-Flow

Navco Pharmaceuticals (TSXV:NAV) Capex-to-Operating-Cash-Flow : 0.00 (As of Mar. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Navco Pharmaceuticals Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Navco Pharmaceuticals's Capital Expenditure for the three months ended in Mar. 2023 was C$0.00 Mil. Its Cash Flow from Operations for the three months ended in Mar. 2023 was C$0.00 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Navco Pharmaceuticals Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Navco Pharmaceuticals's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Navco Pharmaceuticals Capex-to-Operating-Cash-Flow Chart

Navco Pharmaceuticals Annual Data
Trend Jun18 Jun19 Jun20 Jun21
Capex-to-Operating-Cash-Flow
- - - -

Navco Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Navco Pharmaceuticals's Capex-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Navco Pharmaceuticals's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Navco Pharmaceuticals's Capex-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Navco Pharmaceuticals's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Navco Pharmaceuticals's Capex-to-Operating-Cash-Flow falls into.



Navco Pharmaceuticals Capex-to-Operating-Cash-Flow Calculation

Navco Pharmaceuticals's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Jun. 2021 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -0.081
=N/A

Navco Pharmaceuticals's Capex-to-Operating-Cash-Flow for the quarter that ended in Mar. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Navco Pharmaceuticals  (TSXV:NAV) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Navco Pharmaceuticals Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Navco Pharmaceuticals's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Navco Pharmaceuticals (TSXV:NAV) Business Description

Traded in Other Exchanges
N/A
Address
1055 West Georgia Street, Suite 1500, Vancouver, BC, CAN, V6E 4N7
Website
Navco Pharmaceuticals Inc uses of nanotechnology to develop and commercialize novel products to protect against viruses, bacteria, and infectious diseases. The company's pipeline of applications is tailored to defend against pathogens utilizing new methods of action to capitalize on unmet product needs using natural & known compounds, nanoparticles, and no chemicals with a high degree of efficacy. Its target markets include human health & personal skin care, household & institutional products, and veterinary health.

Navco Pharmaceuticals (TSXV:NAV) Headlines

From GuruFocus

Navistar to Sell Melrose Park, Ill. Campus to Developer

By PRNewswire PRNewswire 01-14-2021

Navistar Stockholders Approve Acquisition by TRATON

By PRNewswire PRNewswire 03-03-2021